ANZUPGO
Generic Name/API: delgocitinib.
Manufacturer: LEO Laboratories Ltd.
Dosage Forms & Strength & Pack Size:
Anzupgo 20 mg/g cream one tube 60g
Storage:
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the tube and carton after ‘EXP’. The
expiry date refers to the last day of that month.
Do not freeze.
The tube should be discarded 1 year after first opening.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to
throw away medicines you no longer use. These measures will help protect the environment.
Anzupgo contains the active substance delgocitinib. It belongs to a group of medicines called Janus kinase inhibitors.
Anzupgo is used in adults to treat moderate to severe chronic hand eczema. It is used when corticosteroid skin creams do not work well enough or cannot be used.
Anzupgo targets different proteins (enzymes) in the body called Janus kinases. It works by blocking the activity of four specific Janus kinase enzymes, which helps reduce inflammation and immune responses that cause hand eczema. By suppressing these processes, Anzupgo can help to improve the condition of the skin and reduce itching and pain. This, in turn, can increase the ability to perform daily activities and can improve the quality of life.
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Anzupgo.
Children and adolescents
Do not use this medicine in children and adolescents below the age of 18 years because it has not been studied in this age group.
Other medicines and Anzupgo
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Using Anzupgo at the same time as other medicines on the affected skin is not recommended, as it has not been studied.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
The effects of this medicine in pregnant women are not known; therefore, it is preferable to avoid the use of Anzupgo if you are pregnant or think you may be pregnant.
It is unknown whether delgocitinib passes into human breast milk, but only very small amounts of this medicine are absorbed into the body. No risk to the baby is therefore anticipated and Anzupgo can be used during breast-feeding.
However, if you are breast-feeding, you should take care that this medicine does not to come into contact with your nipple or any other area where your baby may ingest it during feeding.
If you are taking care of a baby, you should also take care to avoid hand contact with the baby’s skin immediately after applying Anzupgo. This is a precaution to limit any unnecessary exposure of the baby to this medicine. In the event of accidental transfer of the cream to the baby’s skin, the cream can be wiped off.
Driving and using machines
This medicine is not expected to have any effect on your ability to drive or to use machines.
Anzupgo contains benzyl alcohol, butylhydroxyanisole, and cetostearyl alcohol
This medicine contains 10 mg of benzyl alcohol (E 1519) in each gram. Benzyl alcohol may cause allergic reactions or mild local irritation.
Butylhydroxyanisole (E 320) may cause local skin reactions (e.g. contact dermatitis) or irritation to the eyes and mucous membranes.
Cetostearyl alcohol may cause local skin reactions (e.g. contact dermatitis).
*The contents of this site are for reference only. We do not offer drug procurement service. All information must not be used for any commercial purpose.
